Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
70.69
+0.63 (0.90%)
Aug 4 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 69.87 - 71.00
52 week 47.36 - 72.31
Open 69.87
Vol / Avg. 4.39M/5.73M
Mkt cap 66.22B
P/E 22.00
Div/yield 0.34/1.90
EPS 3.21
Shares 959.35M
Beta 0.64
Inst. own 55%
Oct 28, 2015
Q3 2015 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated) - 7:00AM EDT - Add to calendar
Sep 3, 2015
Teva Pharmaceutical Industries Ltd Annual Shareholders Meeting - 9:30AM EDT - Add to calendar
Jul 30, 2015
Q2 2015 Teva Pharmaceutical Industries Ltd Earnings Call
Jul 30, 2015
Q2 2015 Teva Pharmaceutical Industries Ltd Earnings Release
Jul 27, 2015
Allergan plc Divests Global Genreics Business to Teva Pharmaceutical Industries Ltd Call
Jul 27, 2015
Teva to Acquire Allergan Generics M&A Call
Jul 27, 2015
Preliminary Q2 2015 Teva Pharmaceutical Industries Ltd Earnings Release
Jul 4, 2015
Israel Investors Conference
Jun 10, 2015
Teva Pharmaceutical Industries Ltd at Goldman Sachs Healthcare Conference
May 13, 2015
Teva Pharmaceutical Industries Ltd at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 9.09% 15.03%
Operating margin 15.03% 19.49%
EBITD margin - 29.59%
Return on average assets 3.89% 6.49%
Return on average equity 7.79% 13.32%
Employees 43,009 -
CDP Score - 89 B

Address

5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company's generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Officers and directors

Yitzhak Peterburg Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Amir Elstein Vice Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Carlo De Notaristefani Ph.D. President and Chief Executive Officer, Global Operations
Age: 57
Bio & Compensation  - Reuters
Robert Koremans M.D. President, Chief Executive Officer - Global Specialty Medicines
Age: 53
Bio & Compensation  - Reuters
Sigurdur Oli. Olafsson President and Chief Executive Officer - Global Generic Medicines Group
Age: 46
Bio & Compensation  - Reuters
Richard S. Egosi Group Executive Vice President, Chief Legal Officer and Company Secretary
Age: 52
Bio & Compensation  - Reuters
Isaac Abravanel Group Executive Vice President - Teva Corporate in Israel and Global Community Alliances
Age: 59
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 49
Bio & Compensation  - Reuters